CCR7 Antibody (SR36-04)

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-67324

Recombinant Monoclonal Antibody.
Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP2-67324
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Validated by

Knockout/Knockdown, Biological Validation

Species Reactivity

Validated:

Human, Mouse, Rat

Cited:

Mouse

Applications

Validated:

Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, Immunoprecipitation, Knockdown Validated, Western Blot

Cited:

IF/IHC

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Rabbit IgG Clone # SR36-04

Concentration

1 mg/ml

View all CCR7 Antibodies »

Product Specifications

Immunogen

Synthetic peptide within Human CCR7 aa 13-62 / 378. (SwissProt: P32248 Human; SwissProt: P47774 Mouse; Unigene:229736 Rat)

Localization

Cell membrane

Clonality

Monoclonal

Host

Rabbit

Isotype

IgG

Scientific Data Images for CCR7 Antibody (SR36-04)

Western Blot: CCR7 Antibody (SR36-04) [NBP2-67324]

Western Blot: CCR7 Antibody (SR36-04) [NBP2-67324]

Western Blot: CCR7 Antibody (SR36-04) [NBP2-67324] - Analysis of CCR7 on different lysates. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in PBS for 1 hour at room temperature. The primary antibody (1/500) was used in 5% BSA at room temperature for 2 hours. Goat Anti-Rabbit IgG - HRP Secondary Antibody at 1:5,000 dilution was used for 1 hour at room temperature. Positive control: Lane 1: Jurkat cell lysateLane 2: MCF-7 cell lysate Lane 3: PC-12 cell lysate Lane 4: Daudi cell lysate
Immunocytochemistry/ Immunofluorescence: CCR7 Antibody (SR36-04) [NBP2-67324]

Immunocytochemistry/ Immunofluorescence: CCR7 Antibody (SR36-04) [NBP2-67324]

Immunocytochemistry/Immunofluorescence: CCR7 Antibody (SR36-04) [NBP2-67324] - Gross and histological appearance of lung excised from 13 weeks of age PyMT transgenic females. CRE treated PyMT transgenic females showed decreased frequency of mammary tumor-derived lung metastases. Immunohistochemistry staining against Ccr7 in lung tissues was done and representative images of tissue sections from each group were taken at 200X and 40X magnification. Scale bars = 50um. Histogram data was presented as mean +/- SEM. * p < 0.05 vs. control. Image collected and cropped by CiteAb from the following publication (https://www.mdpi.com/2072-6643/11/2/410), licensed under a CC-BY license.
Immunohistochemistry-Paraffin: CCR7 Antibody (SR36-04) [NBP2-67324]

Immunohistochemistry-Paraffin: CCR7 Antibody (SR36-04) [NBP2-67324]

Immunohistochemistry-Paraffin: CCR7 Antibody (SR36-04) [NBP2-67324] - Analysis of paraffin-embedded human tonsil tissue using anti-CCR7 antibody. Counter stained with hematoxylin.
View 6 more images

Applications for CCR7 Antibody (SR36-04)

Application
Recommended Usage

Immunocytochemistry/ Immunofluorescence

1:200

Immunohistochemistry-Paraffin

1:200

Western Blot

1:500-1:5000
Application Notes
IP-Assay-dependent

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

TBS (pH7.4), 0.05% BSA, 40% Glycerol

Preservative

0.05% Sodium Azide

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: CCR7

Chemokine receptor 7 (CCR7) is a G-protein coupled receptor (GPCR) that binds chemokine ligand 19 (CCL19) and chemokine ligand 21 (CCL21) and, together, this receptor-ligand interaction functions in inflammatory and adaptive immune response (1,2). The CCR7 protein contains 7-transmembrane spanning alpha helices and is 378 amino acids (aa) in length, with a theoretical molecular weight of 42.8 kDa (3,4). CCR7 is expressed on several cells within the immune system, including naive T cells, central memory T cells, regulatory T cells, naive B cells, a subset of double negative and single positive thymocytes, and mature dendritic cells (DCs) (1, 3).

The primary role of the CCR7/CCL19/CCL21 chemokine signaling axis is homing T cells and DCs to lymph nodes and lymphoid tissues to initiate an immune response (1,2,5,6). In the context of cancer, the CCR7 signaling axis appears to have two opposing roles (2). Downregulation of CCR7 on CD8+ T cells contributes to effector cell migration and anti-cancer activities via cytotoxic tumor-infiltrating lymphocytes (2). However, upregulation of CCR7 by cancer cells can result in cancer cell migration and metastasis (2). Overexpression of CCR7 has been implicated in a variety of cancers including breast, cervical, gastric, head and neck cell carcinoma, and prostate (1,2,7). Studies in breast cancer have found that hypoxia increases CCR7 expression, and this activation can affect cancer cell invasion, extravasation, proliferation, angiogenesis, and metastasis through induction of multiple signaling transduction pathways such as PI3K/AKT, MAPK, and JAK/STAT (5,7).

Given its important role in inflammation and immune response, several strategies have been employed to target the CCR7 signaling axis for cancer immunotherapy (2). Some cancer immunotherapies under investigation include intra-tumoral administration of CCL19 and CCL21, introduction of patient-derived cells transfected to express CCR7 or its ligands, and vaccines (2). Further interrogation of CCR7/CCL19/CCL21 signaling axis is required to develop better therapeutic strategies for cancer treatment.

References:

1. Comerford, I., Harata-Lee, Y., Bunting, M. D., Gregor, C., Kara, E. E., & McColl, S. R. (2013). A myriad of functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the adaptive immune system. Cytokine & growth factor reviews, 24(3), 269-283. https://doi.org/10.1016/j.cytogfr.2013.03.001

2. Salem, A., Alotaibi, M., Mroueh, R., Basheer, H. A., & Afarinkia, K. (2021). CCR7 as a therapeutic target in Cancer. Biochimica et biophysica acta. Reviews on cancer, 1875(1), 188499. https://doi.org/10.1016/j.bbcan.2020.188499

3. Yan, Y., Chen, R., Wang, X., Hu, K., Huang, L., Lu, M., & Hu, Q. (2019). CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention. Frontiers in cell and developmental biology, 7, 212. https://doi.org/10.3389/fcell.2019.00212

4. Uniprot (P32248)

5. Korbecki, J., Grochans, S., Gutowska, I., Barczak, K., & Baranowska-Bosiacka, I. (2020). CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands. International journal of molecular sciences, 21(20), 7619. https://doi.org/10.3390/ijms21207619

6. Sanchez-Sanchez, N., Riol-Blanco, L., & Rodriguez-Fernandez, J. L. (2006). The multiple personalities of the chemokine receptor CCR7 in dendritic cells. Journal of immunology (Baltimore, Md. : 1950), 176(9), 5153-5159. https://doi.org/10.4049/jimmunol.176.9.5153

7. Rizeq, B., & Malki, M. I. (2020). The Role of CCL21/CCR7 Chemokine Axis in Breast Cancer Progression. Cancers, 12(4), 1036. https://doi.org/10.3390/cancers12041036

Alternate Names

BLR2, CC-CKR-7, CCR7, CD197, CDw197, CMKBR7, EBI1

Gene Symbol

CCR7

Additional CCR7 Products

Product Documents for CCR7 Antibody (SR36-04)

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for CCR7 Antibody (SR36-04)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.